State of Alaska Department of Revenue Sells 14,400 Shares of Hologic, Inc. (NASDAQ:HOLX)

State of Alaska Department of Revenue reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 207,789 shares of the medical equipment provider’s stock after selling 14,400 shares during the period. State of Alaska Department of Revenue’s holdings in Hologic were worth $16,197,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of HOLX. McGlone Suttner Wealth Management Inc. acquired a new position in Hologic in the 4th quarter valued at about $27,000. Massmutual Trust Co. FSB ADV lifted its holdings in Hologic by 69.4% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 227 shares during the last quarter. Allworth Financial LP boosted its stake in Hologic by 39.3% in the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 179 shares during the period. Mather Group LLC. acquired a new position in Hologic in the 1st quarter valued at $48,000. Finally, Toth Financial Advisory Corp increased its position in Hologic by 81.1% during the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 347 shares during the period. 94.73% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HOLX. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and upped their price target for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Evercore ISI lowered their target price on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating on the stock in a report on Tuesday. Argus lifted their price target on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Needham & Company LLC reissued a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Friday, May 3rd. Finally, Stephens started coverage on Hologic in a report on Thursday, June 27th. They issued an “overweight” rating and a $87.00 price objective for the company. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Hologic has an average rating of “Moderate Buy” and a consensus price target of $85.55.

Hologic Price Performance

NASDAQ HOLX traded down $0.05 during trading on Wednesday, hitting $73.48. 1,200,364 shares of the company’s stock were exchanged, compared to its average volume of 1,633,806. The stock’s 50 day moving average price is $74.21 and its two-hundred day moving average price is $74.36. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $82.45. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The company has a market cap of $17.15 billion, a PE ratio of 37.52, a P/E/G ratio of 2.47 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The firm’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.06 EPS. Research analysts expect that Hologic, Inc. will post 4.08 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.